Business Context and Reporting Period
Company: Pavmed Inc. (Emerging Growth Company)
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2018
Event: Entry into a Material Definitive Agreement involving Lucid Diagnostics Inc., a majority-owned subsidiary of Pavmed.
Key Financial Metrics and Transaction Details
This filing details a strategic transaction rather than periodic financial performance. Key financial terms include:
- License Fee: Noncash equity in Lucid Diagnostics Inc. issued to Case Western Reserve University (CWRU).
- Reimbursement Obligation: Lucid must reimburse CWRU for accumulated patent development costs estimated at approximately $272,553.
- Payment Terms: $50,000 paid at closing (funded initially by Pavmed, to be repaid by Lucid upon its initial capital raise); the balance payable quarterly subject to financing conditions.
- Future Obligations: Royalties based on net sales of the EsoCheck product and minimum yearly royalties commencing the year after the first commercial sale.
- Equity Issuance: 10,000,000 shares of Lucid common stock issued at closing, including 8,187,499 shares to Pavmed.
Material Changes and Agreements
On May 12, 2018, Lucid Diagnostics entered into a patent license agreement with CWRU. Material changes include:
- Intellectual Property: Lucid acquired an exclusive worldwide license for the EsoCheck Technology (balloon sampling device and DNA biomarkers).
- Corporate Structure: Lucid will operate as a separate entity, raising its own capital and recruiting a separate management team.
- Management Services: A management services agreement was executed where Lucid compensates Pavmed for administrative services.
- Shareholder Rights: A shareholders agreement includes transfer restrictions, co-sale rights, and drag-along rights.
- Termination: The agreement terminates upon patent expiration or May 12, 2038, whichever is later.
Outlook, Risks, and Contingencies
Management Commentary and Milestones: The agreement is subject to regulatory and commercialization milestones. Payments are due upon achieving certain milestones. If Lucid fails to achieve specific milestones, CWRU has the right to require Pavmed to transfer up to 100% of its Lucid shares to CWRU.
Risks and Contingencies:
- Capital Raise Dependency: The repayment of the initial $50,000 advance to Pavmed is contingent on Lucid's initial capital raise from independent investors.
- Equity Dilution Risk: Failure to meet milestones could result in the loss of Pavmed's equity stake in Lucid.
- Regulatory Approval: Commercialization depends on FDA or other government agency approvals for exclusive marketing rights.
Investor Verification Checklist
- Verify the exact percentage of Lucid Diagnostics equity held by CWRU and the physician inventors following the issuance of 10,000,000 shares.
- Confirm the specific regulatory and commercialization milestones that trigger equity transfer rights for CWRU.
- Monitor Lucid's progress in securing independent capital to repay the $50,000 advance provided by Pavmed.
- Review the vesting schedule and strike prices for the options granted to physician inventors (100,000 Lucid shares at $0.50; 25,000 Pavmed shares at $1.59).